Company Description
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe.
The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma.
It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe.
The company was founded in 1987 and is headquartered in New York, New York.
| Country | United States |
| Founded | 1988 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 96 |
| CEO | Gerard Michel |
Contact Details
Address: 566 Queensbury Avenue New York, New York 12804 United States | |
| Phone | 212-489-2100 |
| Website | delcath.com |
Stock Details
| Ticker Symbol | DCTH |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000872912 |
| CUSIP Number | 24661P807 |
| ISIN Number | US24661P8077 |
| Employer ID | 06-1245881 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Gerard J. Michel MBA, MS | Chief Executive Officer and Director |
| Dr. Martha S. Rook Ph.D. | Chief Operating Officer |
| Dr. Vojislav Vukovic M.D., M.Sc., Ph.D. | Chief Medical Officer |
| Sandra Pennell CPA | Chief Financial Officer |
| David Hoffman J.D. | General Counsel, Corporate Secretary and Chief Compliance Officer |
| Dr. Johnny John M.D. | Senior Vice President of Clinical Operations and Medical Affairs |
| Dr. Michael Brunner M.D. | Senior Vice President of Interventional Oncology |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 1, 2025 | ARS | Filing |
| Apr 1, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 1, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 21, 2025 | 8-K | Current Report |
| Mar 6, 2025 | 10-K | Annual Report |
| Mar 6, 2025 | 8-K | Current Report |
| Jan 27, 2025 | SCHEDULE 13D/A | Filing |
| Jan 13, 2025 | 8-K | Current Report |
| Dec 30, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |